S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

NCT01668719 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

142

Enrollment

NETWORK

Sponsor class

Conditions

DS Stage I Plasma Cell Myeloma
DS Stage II Plasma Cell Myeloma
DS Stage III Plasma Cell Myeloma

Interventions

DRUG: Bortezomib
DRUG: Dexamethasone
BIOLOGICAL: Elotuzumab
OTHER: Laboratory Biomarker Analysis
DRUG: Lenalidomide

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]